Ga-68 dotatate
FDA-approved PET imaging agent for somatostatin-receptor–positive NETs (Netspot).
What it's for
FDA-approved PET imaging agent for somatostatin-receptor–positive NETs (Netspot).
What it's for
Gallium Ga-68 dotatate is a positron-emitting diagnostic agent in which Ga-68 is chelated to DOTA-TATE, a somatostatin-analog peptide. It is used with PET to localize somatostatin receptor–positive neuroendocrine tumors (NETs).
What it does for the body
It is used with PET to localize somatostatin receptor–positive neuroendocrine tumors (NETs). People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
DOTA-TATE binds somatostatin receptors (lock-and-key landing spots on cells) subtype 2 on neuroendocrine tumor cells; Ga-68 decay enables PET imaging of receptor-positive lesions. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Ga-68 dotatate has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Ga-68 dotatate — FDA.gov search
- ClinicalTrials.gov search: Ga-68 dotatate — U.S. clinical trials registry
- Drugs@FDA search: Ga-68 dotatate — FDA drug database (if approved)
- PubMed search: Ga-68 dotatate — NCBI PubMed
- PubMed Central search: Ga-68 dotatate — NCBI PMC